54 NATURAL INGREDIENTS
Effect of Pyrus Malus Juice on HaCat Cells viability (% relative to control)
200 175 150 125 100 75 50 25 0
Effect of Pyrus Malus Juice 5% vs Placebo at T0 and T30 mins
* * * *
60 50 40 30 20 10 0
0.01 0.05 0.1 0.5 Figure 1: Effects of Pyrus malus juice on HaCaT Cells
(DMEM) supplemented with 10% foetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% glutamine, maintained at 37°C in a 5% CO2 humidified incubator. For testing, cells were seeded into 96-well plates at a density of 1x104
1 Pyrus Malus Juice Concentration (% volume) 10% FBS
Figure 2: Effect of Pyrus malus juice versus placebo. * for p < 0.05 within each group (T0 vs T30 mins). ** for p = 0.001 in the comparison between groups (difference between variations)
cells/well and allowed
to adhere for 24 hours. Treatment involved exposing cells to serial dilutions of the active ingredient (Pyrus malus juice) at concentrations ranging from 0.01% to 1% v/v in serum-free medium. Glycerin (commonly used in cosmetic products as a standard hydrating agent) served as a positive control. Tested substances included Pyrus malus juice, glycerin, sodium benzoate, potassium sorbate. After 24 hours of incubation with the test
substances, cellular metabolic activity was evaluated using the MTS assay (a colorimetric method for assessing mitochondrial function). Absorbance was measured at 490 nm, with values directly proportional to the number of viable, metabolically active cells. All experiments were conducted in triplicate.
Statistical significance was assessed using unpaired two-tailed t-tests to compare treated samples to control (glycerin and untreated), with significance set at p < 0.05.
In vivo evaluation of skin hydration The study tested a cosmetic formulation containing the active fruit-derived ingredient against a placebo (identical base formulation without the active). Applications were made to the volar forearms of each subject in a split-body design to eliminate inter-subject variability. The study involved ten healthy volunteers with
an average age of 47.8 years. Informed consent was obtained from all participants in accordance with the Declaration of Helsinki. The study was designed as a controlled, comparative, randomized trial with double-arm treatment (active versus placebo on opposite forearms). The formulations for the in vivo efficacy test were
as follows. Active product: Aqua, Pyrus Malus Juice, Glycerin, Carbomer, Sodium Hydroxide, Sodium Ethylparaben, Sodium Propylparaben; placebo product: Aqua, Carbomer, Sodium Hydroxide, Sodium Ethylparaben, Sodium Propylparaben. The inclusion criteria were: Caucasian subjects
of either sex, aged 18–70; general good health and ability to comply with study procedures; avoidance of UV exposure and tanning beds during the study. The exclusion criteria were: pregnancy,
breastfeeding, known skin sensitivities; ongoing treatment with systemic or topical agents affecting
Variation of skin hydration registered after 30 minutes from the single application ***
20 15 10 5 0
-5 -10 Pyrus malus Juice 5% Placebo
Figure 3: Variations of skin hydration registered after 30 minutes from single application
PERSONAL CARE MAGAZINE April 2026 +15.8%
skin; dermatological disorders (e.g. eczema, psoriasis); participation in similar trials within the last 30 days. A 3x3 cm area on each forearm was marked for treatment. A fixed amount of 2 mg/cm2
of either the
active product or placebo was applied post-baseline measurement. Applications were performed twice daily (morning and evening) for 30 days.
Instrumental assessment Surface skin hydration was measured with Corneometer® CM 825 (Courage & Khazaka). Deep skin hydration was measured with MoistureMeterEpiD (Delfin Technologies). All measurements were performed in a
climate-controlled room (24 ± 2°C; 50 ± 10% RH). Volunteers refrained from washing forearms for two hours and from applying any skin care product for at least 12 hours before testing. ■ T0: Baseline (before application) ■ T1: 30 minutes post-application (single dose) ■ T2: Day 30 (after twice-daily application for one month)
Results In vitro cellular revitalization6 All tested concentrations of Pyrus malus juice
Comparison of Pyrus malus Juice vs Placebo
-8.1%
60 50 40 30 20 10 0
43.7% 43.2%
Pyrus Malus Juice ■ Placebo ■
51.9% * ** 43.0% * ** * TO ■ T30 mins ■
Pyrus Malus Juice 5%
Placebo
T0
T30 days
Figure 4: Comparison of the effects of Pyrus malus juice 5% versus placebo over 30 days
www.personalcaremagazine.com
Variation in hydration (%)
Viability (% relative to control
Mean Value
Mean Value
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152
